Metabolic Dysfunction Associated Fatty Liver Disease in Healthy Weight Individuals

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2024 Jul 25

PMID 39052203

Authors

Nahum Mendez-Sanchez

Willem Pieter Brouwer

Frank Lammert

Yusuf Yilmaz

Affiliations

Soon will be listed here.

Abstract

Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasing public health problem, affecting one third of the global population. Contrary to conventional wisdom, MAFLD is not exclusive to obese or overweight individuals. Epidemiological studies have revealed a remarkable prevalence among healthy weight individuals, leading investigations into the genetic, lifestyle, and dietary factors that contribute to the development of MAFLD in this population. This shift in perspective requires reconsideration of preventive strategies, diagnostic criteria and therapeutic approaches tailored to address the unique characteristics of MAFLD healthy weight individuals. It also underscores the importance of widespread awareness and education, within the medical community and among the general population, to promote a more inclusive understanding of liver metabolic disorders. With this review, we aim to provide a comprehensive exploration of MAFLD in healthy weight individuals, encompassing epidemiological, pathophysiological, and clinical aspects.

Citing Articles

Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis.

Lakhdhir F, Muhammad A, Qureshi A, Shaikh I, Joher I, Majeed J Cureus. 2024; 16(10):e71639.

PMID: 39553144 PMC: 11567170. DOI: 10.7759/cureus.71639.

Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols.

Tauil R, Golono P, de Lima E, de Alvares Goulart R, Landgraf Guiguer E, Bechara M Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458995 PMC: 11510109. DOI: 10.3390/ph17101354.

References

Li M, Cai S, Boyer J . Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects Med. 2017; 56:45-53. PMC: 5662014. DOI: 10.1016/j.mam.2017.06.001. View

Sinn D, Kang D, Cho S, Paik S, Guallar E, Cho J . Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2021; 33(1S Suppl 1):e529-e534. DOI: 10.1097/MEG.0000000000002158. View

Kawaguchi T, Tsutsumi T, Nakano D, Torimura T . MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res. 2021; 52(5):422-432. DOI: 10.1111/hepr.13706. View

Fukunaga S, Nakano D, Tsutsumi T, Kawaguchi T, Eslam M, Yoshinaga S . Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatol Res. 2022; 52(8):699-711. DOI: 10.1111/hepr.13795. View

Arikan D, Onmez A, Aksu E, Tasdemir N . Predictivity of fatty liver index for non-alcoholic fatty liver disease in lean females with polycystic ovary syndrome. Afr Health Sci. 2022; 22(1):648-656. PMC: 9382525. DOI: 10.4314/ahs.v22i1.75. View

Xie C, Chen L, Lin C, Hu C, Chien C . Serum Uric Acid but Not Ferritin Level Is Associated with Hepatic Fibrosis in Lean Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease: A Community-Based Study. J Pers Med. 2022; 12(12). PMC: 9782820. DOI: 10.3390/jpm12122009. View

Park H, Yoon E, Ito T, Jo A, Kim M, Lee J . Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2023; 6(8):e2329568. PMC: 10436134. DOI: 10.1001/jamanetworkopen.2023.29568. View

Krawczyk M, Liebe R, Lammert F . Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond. Gastroenterology. 2020; 158(7):1865-1880.e1. DOI: 10.1053/j.gastro.2020.01.053. View

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79(6):1542-1556. DOI: 10.1016/j.jhep.2023.06.003. View

10.

van Meer S, van Erpecum K, Sprengers D, Klumpen H, Jansen P, IJzermans J . Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. Eur J Gastroenterol Hepatol. 2016; 28(8):955-62. DOI: 10.1097/MEG.0000000000000641. View

11.

Fu C, Wai J, Mustapha N, Irles M, Wong G, Mahadeva S . Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019; 18(12):2843-2845.e2. DOI: 10.1016/j.cgh.2019.09.027. View

12.

Eslam M, El-Serag H, Francque S, Sarin S, Wei L, Bugianesi E . Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022; 19(10):638-651. DOI: 10.1038/s41575-022-00635-5. View

13.

Amirkalali B, Khoonsari M, Sohrabi M, Ajdarkosh H, Motamed N, Maadi M . Relationship between dietary macronutrient composition and non-alcoholic fatty liver disease in lean and non-lean populations: a cross-sectional study. Public Health Nutr. 2021; 24(18):6178-6190. PMC: 11148619. DOI: 10.1017/S1368980021001762. View

14.

Wang Q, You H, Ou X, Zhao X, Sun Y, Wang M . Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatol Int. 2019; 13(6):766-776. DOI: 10.1007/s12072-019-09982-z. View

15.

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

16.

Barber T, Hanson P, Weickert M . Metabolic-Associated Fatty Liver Disease and the Gut Microbiota. Endocrinol Metab Clin North Am. 2023; 52(3):485-496. DOI: 10.1016/j.ecl.2023.01.004. View

17.

Ha J, Yim S, Karagozian R . Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022; 21(10):2496-2507.e5. DOI: 10.1016/j.cgh.2022.11.019. View

18.

Ji Y, Yin Y, Li Z, Zhang W . Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients. 2019; 11(8). PMC: 6724003. DOI: 10.3390/nu11081712. View

19.

Fukunaga S, Mukasa M, Nakane T, Nakano D, Tsutsumi T, Chou T . Impact of non-obese metabolic dysfunction-associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study. Hepatol Res. 2023; 54(2):201-212. DOI: 10.1111/hepr.13973. View

20.

Lee G, You H, Bajaj J, Joo S, Yu J, Park S . Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun. 2020; 11(1):4982. PMC: 7536225. DOI: 10.1038/s41467-020-18754-5. View